Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

Tri-Specific Fusion Protein αPD-1/αVEGF/IL-21v Shows Enhanced Antitumor Efficacy

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSuna KimSCSunjung ChoHBHyojoo Bang

Discussion

Loading...

Member takes

Overview

Novel tri-specific fusion protein improves T cell activation and antitumor responses in resistant tumors, suggesting new therapeutic strategies.

Key Points

  • To evaluate the efficacy of a tri-specific fusion protein, αPD-1/αVEGF/IL-21v, in improving antitumor immunity.
  • Developed a tri-specific fusion protein targeting PD-1, VEGF, and IL-21v.
  • Tested in vitro using PD-1+/PD-1- HuT78 cells and TME-mimicking conditions.
  • Evaluated antitumor efficacy in an ICI-resistant MC38 tumor model.
  • αPD-1/αVEGF/IL-21v showed comparable PD-1/PD-L1 blocking and VEGF/VEGFR inhibition to existing therapies.
  • Enhanced secretion of IFN-γ and granzyme B from PD-1high T cells compared to αPD-1/αVEGF.
  • Increased CD8+ T/Treg ratio and memory T cell populations within tumors, leading to superior antitumor efficacy without adverse effects.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/69d1fc8ea79560c99a0a21e7https://doi.org/10.1158/1538-7445.am2026-4341
View Full Paper
Ask AI
Bookmark
Share